1
1
4
↑1
↓1
—4
Evidence suggests Psilocybin haslittle to no effecton Safety.
8 studies (6 claims)
Emerging evidence
Typical effective dose 25 (25–25) mgacross 2 dosed studies
Study Claims
| Intervention | Direction | Endpoint | Type | Population | Dosage | Title |
|---|---|---|---|---|---|---|
| psilocybin therapy | Decreases - was unsafe even under medical supervision | safety perception | Human | psychiatrists in Ireland | Not mentioned | Amid magic and menace: psychiatrists' attitudes to psilocybin therapy. |
| psilocybin-assisted therapy | Increases - create a haptic experience during the psilocybin session that reinforces the participants' sense of safety | participants' sense of safety | Human | participants | Not specified | Evolving Guidelines for the Use of Touch During a Clinical Trial of Group Psilocybin-Assisted Therapy. |
| Psilocybin-assisted therapy (PAT) | No effect - well-tolerated | safety | Human | people with FM | Two oral doses (15 mg and 25 mg) administered two weeks apart. | Preliminary safety and effectiveness of psilocybin-assisted therapy in adults with fibromyalgia: an open-label pilot clinical trial. |
| psilocybin-assisted psychotherapy | No effect - safety is generally supported | safety | Human | clinical populations | Heterogeneous doses (specific amounts not detailed in the abstract). | The safety of psilocybin-assisted psychotherapy: A systematic review.cited 1× |
| psilocybin-assisted psychotherapy | No effect - will be investigated for | safety | Human | approximately 15 people with cancer-related PGD | 25 mg psilocybin (single psychoactive dose). | Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement. |
| psilocybin-assisted psychotherapy | No effect - will be evaluated for | safety | Human | approximately 15 people with cancer-related PGD | 25 mg psilocybin (single psychoactive dose). | Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief (PARTING) trial: protocol for an open-label pilot trial for cancer-related bereavement. |
| psilocybin | No effect - generally safe | safety profile | Human | — | Single 25 mg dose mentioned in the largest clinical trial. | Psychedelic Therapy: A Primer for Primary Care Clinicians-Psilocybin.cited 7× |